Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience

• DOI: 10.3899/jrheum.141567
• Publication Date: 2015-06-02T13:47:45Z
• Authors: Manuela Pardeo; Denise Pires Marafon; Antonella Insalaco; Claudia Bracaglia; Rebecca Nicolai; Virginia Messia; Fabrizio De Bened...
• Keywords: Adult-onset Still's disease; Concomitant; Single Center

To assess anakinra as a therapy for systemic juvenile idiopathic arthritis (sJIA) in single-center series.We reviewed 25 patients with sJIA treated at least 6 months. The primary outcome was the number of who achieved clinically inactive disease months, according to preliminary criteria and clinical remission JIA.Among evaluated, 14 (56%) met months were classified responders. For each individual patient, we compared dose administered ideal found that there no relation response. We also demographic characteristics laboratory features baseline responders non-responders: differences observed active joints before starting or concomitant glucocorticoids treatment. only variable significantly associated response time from onset receiving anakinra, earlier treatment being better outcome.Anakinra is rapid attainment significant portion patients. outcome. However, formal studies on early pathophysiology treatments, including early- late-onset are needed optimize management this challenging disease.